| ABOUT HABERMAN ASSOCIATES |
We consult,
write, and speak on critical issues that determine the success of life
science companies. Working together with our partners in the Biopharmaceutical
Consortium, we help your company increase the effectiveness
of its drug and diagnostic discovery and development, commercialization
of new research products, assessment of new business opportunities, and
partnering.
Our typical consulting engagements have included:
Strategic new
product and R&D planning
Opportunity
assessment and assistance in partnering
Technology
assessment
Assessment
of pipeline drugs and assistance in go/no go decisions
Proprietary
strategic reports on areas for potential business expansion
Due diligence
on potential partners and investment or acquisition candidates
For further details on consulting services we have provided, please click here.
Our clients principally include pharmaceutical, biotechnology, diagnostics,
and research products companies of all sizes, from startups to major corporations.
We serve clients on a worldwide basis, mainly in North America, Europe,
and Japan.
Our
books
and reports have been published by such leading organizations as Decision
Resources, Cambridge Healthtech Institute, and Informa Healthcare.
Our
articles
have appeared in such leading publications as Genetic Engineering News,
Pharma
DD, and PharmaWeek. See our
home
page for examples.
Our principal,
Allan B. Haberman, has been
quoted in such publications as Pharmaceutical
Executive,
Business Week, New Scientist,
Mass High
Tech, and
Sacramento Business Journal.
We also speak
and teach in business and academic settings.
